Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016

Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016
Published Jun 28, 2016
61 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016, provides in depth analysis on Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted pipeline therapeutics.

The report provides comprehensive information on the Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18)
- The report reviews Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects
- The report assesses Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics

Reasons to buy

- Gain strategically significant

  
Source:
Document ID
GMDHC0119TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Overview71
Therapeutics Development83
  Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Stage of Development81
  Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Therapy Area91
  Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Indication101
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Pipeline Products Glance111
  Early Stage Products111
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Companies122
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Universities/Institutes142
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Therapeutics Assessment165
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action171
  Assessment by Route of Administration182
  Assessment by Molecule Type201
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Companies Involved in Therapeutics Development214
  Chong Kun Dang Pharmaceutical Corp.211
  SynDevRx, Inc.221
  Takeda Pharmaceutical Company Limited231
  Zafgen Inc.241
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Drug Profiles2517
  beloranib Drug Profile258
  Drugs to Inhibit Methionine Aminopeptidase 2 for Obesity Drug Profile331
  fumagillin Drug Profile341
  ligerin Drug Profile351
  lodamin Drug Profile361
  RSF-101 Drug Profile371
  SDX-7320 Drug Profile381
  Small Molecules to Inhibit MAP2 for Obesity Drug Profile391
  Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders Drug Profile401
  ZGN-839 Drug Profile411
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Dormant Projects422
Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Featured News &Press Releases4416
  Jun 11, 2016: Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Associations 76th Scientific Sessions442
  Apr 03, 2016: Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016462
  Mar 28, 2016: Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016481
  Feb 18, 2016: Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint491
  Jan 20, 2016: Zafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints502
  Dec 02, 2015: Zafgen Announces Beloranib IND Placed on Complete Clinical Hold521
  Dec 02, 2015: Zafgen Provides Clinical Update on Beloranib521
  Oct 22, 2015: Zafgen Announces Beloranib Program Update531
  Oct 16, 2015: Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials541
  Oct 14, 2015: Zafgen Issues Statement541
  Sep 30, 2015: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma551
  Sep 09, 2015: Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes551
  May 28, 2015: Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome561
  May 08, 2015: Zafgen Presents Positive Safety And Efficacy Data From Phase 2 Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015571
  May 07, 2015: Zafgen Announces Oral And Poster Presentations At The 22nd European Congress On Obesity582
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Methionine-Aminopeptidase-2-MAP-2-or-Peptidase-M-2-or-eIF-2-a-Associated-p67-Homolog-or-EC-3-4-11-18-Pipeline-Review-H1-2016-2088-16032>
  
APA:
Global Markets Direct - Market Research. (2016). Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Methionine-Aminopeptidase-2-MAP-2-or-Peptidase-M-2-or-eIF-2-a-Associated-p67-Homolog-or-EC-3-4-11-18-Pipeline-Review-H1-2016-2088-16032>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.